Verizon Announces Quarterly Dividend & Record/Payable Date

Verizon Communications, Inc. (VZ) is a worldwide leader in delivering communications and technology solutions that improve the lives of its customers.

Verizon’s Board of Directors declared a quarterly dividend of $0.59 per outstanding share. The dividend was unchanged from the last quarter. The dividend will be payable May 1, 2018 to those shareholders of record on April 10, 2018 at the close of business.

To learn more about Verizon Communications, Inc. (VZ) and to track its progress please visit the Vista Partners Verizon Communications Inc. Coverage Page.

3/6/18: Verizon declares quarterly dividend

The Board of Directors of Verizon Communications Inc. today declared a quarterly dividend of 59 cents per outstanding share, unchanged from the previous quarter…

Read Full Article

The Home Depot Will Put $50 Million Towards Skilled Trades Training

The Home Depot, Inc. (HD) is the world’s largest home improvement retailer with retail stores all across North America. The Home Depot sells building materials and home improvement products, as well as lawn and garden supplies, and provides installation, home maintenance, and professional service programs.

The Home Depot Foundation has committed $50 million to the training of 20,000 tradespeople over the course of the next 10 years. This commitment will help to fill the growing skilled labor gap.

Last year, The Home Depot Foundation partnered with Home Builders Institute, a nonprofit, to start a pilot trades training program for separating military members at Fr. Stewart and Ft. Bragg. The first class from the 12-week pre-apprenticeship certification program is set to graduate this month. The program is provided to its students at no cost and will roll out on additional United States bases.

We want to bring shop class back, from coast-to-coast. We’re thrilled to train 20,000 next-generation plumbers, electricians, carpenters and beyond. It’s a true honor to welcome our first classes of separating soldiers as they transition to civilian life and into successful careers in the trades.” -Shannon Gerber, executive director of The Home Depot Foundation

The company’s foundation is also working with the Construction Education Foundation of Georgia to establish an advanced level trades training program for the residents of Atlanta’s Westside community, and eventually into under-served high schools across the US.

To learn more about The Home Depot, Inc. (HD) and to continue to track its progress please vista Partners The Home Depot, Inc. Coverage Page.

The Home Depot Foundation Commits $50 Million to Skilled Trades Training

The Home Depot Foundation Commits $50 Million to Skilled Trades Training Foundation to train 20,000 new tradespeople by 2028 to fill labor gap ATLANTA, March 8, 2018 /PRNewswire/ — Today,..

Read Full Article

Coca-Cola Refranchising Canadian Bottling Operations

The Coca-Cola Company (KO) is the largest total beverage company in the world. It offers 500 plus brands in over 200 countries, and is committed to reducing sugar in its drinks and providing new and diverse drinks to people everywhere.

Larry Tanenbaum O.C. and Junior Bridgeman have both signed non-binding Letters-of-Intent to obtain Coca-Cola Refreshments Canada, The Coca-Cola Company’s Canadian bottling and distribution company.

The acquirement of the Canadian-based bottling company will be a joint venture between Tanenbaum and Bridgeman. Tanenbaum is a distinguished businessman and philanthropist. Bridgement, who is a former NBA player, is also an esteemed entrepreneur and the current President and CEO of the Kansas-based Heartland Coca-Cola Bottling Company.

Coca-Cola Refreshments Canada currently employs about 5800 associates and operates five facilities, over 50 sales and distribution centers, and does business in all of the country’s 10 provinces and three territories.

The non-binding Letter of Intent begins the final step in completing the refranchising of Coca-Cola’s company-owned bottling operations in North America. The Letter of Intent is subject to both parties reaching a definitive agreement, and the transaction is predicted to close in the latter half of 2018.

To learn more about The Coca-Cola Company (KO) and to continue to track its progress please visit the Vista Partners Coca-Cola Company Coverage Page.

The Coca-Cola Company Announces Letter of Intent for Refranchising of Canadian Bottling Operations


Read Full Article

Travelers Partners With Companies To Help Find Treatment For Acute Orthopedic Injuries

The Travelers Companies, Inc. (TRV) is an insurance provider of property casualty insurance for home, auto, and business.

The Travelers Companies, Inc. will be partnering with Cedars-Sinai, Samsung Electronics Americ, Bayer, and appliedVR to research the effects of therapeutic virtual reality and wearable technology as an alternative way to manage pain. They will be focusing specifically on acute orthopedic injuries of the lower back and extremities.

The clinical research project will take place at Cedars-Sinai’s Center for Outcomes Research and Education and will last over 16 months. The project will include between 90 and 140 participants with ages ranging from 18 to 65.

Workplace injuries that lead to chronic pain can cause ongoing issues, as an injured employee may mask pain with opioids or other drugs. Identifying new, non-pharmacologic alternatives for pain management can help an injured employee avoid chronic pain, lower the chances that they will develop a dangerous opioid addiction and reduce medical costs. We are grateful for this partnership and look forward to seeing the results that Dr. Brennan Spiegel and the Cedars-Sinai team uncover using the latest technology from appliedVR, Bayer and Samsung.” – said Dr. Melissa Burke, National Pharmacy Director at Travelers

To learn more about The Travelers Companies, Inc. (TRV) and to continue to track its progress please visit the Vista Partners Travelers Companies, Inc. Coverage Page.

Press Release | Travelers Insurance


Read Full Article

Caterpillar Launches Water Campaign

Caterpillar, Inc. (CAT) is the world’s chief manufacturer of diesel and natural gas engines, construction and mining equipment, industrial gas turbines, and diesel-electric locomotives. Caterpillar, Inc. works to make sustainable progress possible and contributes to driving positive change on every continent.

Water is a critical need of people and communities, yet almost 844 million people do not have access to clean, safe water.

The Caterpillar Foundation has launched the Value of Water Campaign to raise the awareness of the impact of the global water crisis on education, economics, and community health. This is one step on the foundation’s mission to help empower 50 million people globally to rise out of extreme poverty by the year 2020.

The Caterpillar Foundation will be working with multiple partners including water, Ducks Unlimited, Global Citizen, Living Land & Waters, Opportunity International, The Nature Conservancy and

Various aspects addressed in the Campaign include:

  • Bringing clean water to rural communities in Africa through construction of new wells and innovative pipe systems
  • Restoring critical wetland habitats that provide flood protection and water filtration
  • Reducing river pollution throughout the United States
  • Strengthening the health of the world’s vital rivers
  • Delivering running water to homes in Africa, Asia, and South America through micro credit loans

“As the company and its customers work to build traditional infrastructure, the Caterpillar Foundation is focused on building human infrastructure, and ultimately, a better world,” said Caterpillar Foundation President Michele Sullivan. “Water is a fundamental human need – it is a basic building block necessary to pursue opportunities such as education and economic growth, and place people on a path to prosperity.” -Michele Sullivan, Caterpillar Foundation President

To learn more about the Value of Water Campaign and how to become involved visit

To learn more about Caterpillar, Inc. (CAT) and to continue to track its progress please visit the Vista Partners Caterpillar, Inc. Coverage Page.

Caterpillar Foundation Launches Value of Water Campaign to Help its Partners Address Poverty


Read Full Article

The Dow Chemical Company Launches ECOFAST Textile Treatment

The Dow Chemical Company is a part of the DowDupont Holding Company (DWDP), a business that is focused on agriculture, materials science and specialty product sectors that will lead their respective industries through productive, science-based innovation to meet the needs of customers and help solve global challenges.

This week at the American Association of Textile Chemist and Colorists (AATCC), The Dow Chemical Company launched ECOFAST Pure Sustainable Textile Treatment. The technology in this treatment allows for unique and more vibrant colors on natural textiles and greatly improves the efficient use of resources during the dyeing process. With the new technology, fluorescents are now available for use on cotton. The treatment allows the uptake of reactive, direct, and acid dyes on natural fibers and fabrics. ECOFAST Pure also improves the color quality of a product, so that the color will last longer.

Dow has leveraged over a century of material science knowledge to help address the performance and sustainability gaps in the textile industry. By pretreating textiles with ECOFAST Pure, manufacturers can deliver longer lasting, new generation colors on natural textiles while simultaneously reducing water, dye and energy use.” – Esma Talu, market manager for Dow

To learn more about Dow and DowDuPont (DWDP) and to continue to track its progress please visit the Vista Partners DowDuPont Coverage Page.

Dow Product Enables Brighter Colors on Natural Textiles

Dow will launch ECOFAST™ Pure Sustainable Textile Treatment at the American Association of Textile Chemists and Colorists International Conference…

Read Full Article

Sonia Cargan is New Chief Diversity Officer of American Express

American Express Company (AXP), and its subsidiaries, provide customers and businesses globally with charge and credit payment card products and travel-related services. They look to enrich the lives of their customers and build business success.

Sonia Cargan has been appointed the chief diversity officer of American Express Company. With this appointment, Cargan’s job will be to ensure that American Express is an employer choice of top diverse talent and that it continues to drive unified success through a collaborative work environment and growth of inclusive teams. Cargan will also work to serve the company’s 15 colleague networks to promote a culture of inclusion and development opportunities.

Cargan received her Bachelor of Arts Honors degree in social administration from the University of Brighton and has held a 22-year career with American Express Company.

Sonia is a long-time advocate of the business results that can be achieved through the development of a diverse and inclusive organization. As an executive with a wealth of global experience, she is also ideally suited to continue to elevate and evolve our diversity and inclusion strategies through a global lens.” – Kevin Cox, chief human resources officer, American Express

To learn more about American Express Company (AXP) and to continue to track its progress please visit the Vista Partners American Express Coverage Page.

American Express Names Sonia Cargan as Chief Diversity Officer


Read Full Article

Breast Cancer Therapeutics Innovator Atossa Genetics 2017 Results & Recent Developments Highlighted

Seattle based Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.

Today Atossa announced the following recent developments:

Successful Phase 1 Study

All objectives of Atossa’s recent Phase 1 study of its proprietary oral and topical formulations of Endoxifen were successfully met: there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of Atossa’s oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen.

TRAP CAR-T Program

In October 2017, they announced that they are developing a novel method to deliver CAR-T cells into the ducts of the breast for the potential targeted treatment of breast cancer. This approach uses their proprietary intraductal microcatheter technology for the potential transpapillary, or “TRAP,” delivery of either T-cells that have been genetically modified to attack breast cancer cells or various immunotherapies.

They believe this method has several potential advantages including the reduction of toxicity by limiting systemic exposure of the T-cells or immunotherapy; improved efficacy by placing the T-cells or immunotherapy in direct contact with the target ductal epithelial cells that are undergoing malignant transformation; and, lymphatic migration of the CAR-T cells or immunotherapy potentially extending their cytotoxic actions into the regional lymph system, which could limit tumor cell dissemination. Their approach is in the R&D stage and is currently not FDA approved.

Expansion of Scientific Advisory Board

At the end of 2017, they added Dr. Carl Novina to our Scientific Advisory Board. Together with Dr. Jack Cuzick, they now have a world-renowned group advising on the scientific and medical aspects of their programs.

Capital Raising Activity

In 2017, they made significant improvements to their balance sheet by raising approximately $12 million in capital, which strengthened their balance sheet and improved their stockholder base with the addition of institutional biotech-focused investors.

Atossa also provided the following 2018 potential milestones:

First half of 2018 – opening the Phase 2 Study of topical Endoxifen to treat MBD at Stockholm South General Hospital in Sweden (which they plan to complete in 2018)

First half of 2018 – opening the Phase 2 Study of oral Endoxifen to treat patients who are not responding to Tamoxifen (which they plan to complete in 2018).

Second half of 2018 – commencing one or more studies to demonstrate safety and efficacy of administering TRAP CAR-T or another immunotherapy with their microcatheters.

Throughout 2018 – Identifying additional opportunities for their Endoxifen formulations; and Continuing our Phase 2 study administering Fulvestrant with their microcatheters.

Dr. Steve Quay, President and CEO, commented, “In the later part of 2017, we completed a Phase 1 Study of our proprietary oral and topical Endoxifen formulations, and we were pleased to report that all study objectives were met. We are now looking forward to opening enrollment in two Phase 2 studies.  One will use our oral Endoxifen to treat breast cancer patients who are not responding to tamoxifen.  Tamoxifen is the current FDA-approved standard of care for the approximately one million breast cancer survivors to prevent a recurrence and new cancer.  The second study will use our topical Endoxifen to determine if it can reduce a condition called mammographic breast density, or MBD.  Mammographic Breast Density is an independent risk factor for developing breast cancer.  It affects approximately 10 million women in the U.S.  We are also planning to commence an additional study with topical Endoxifen as well as a study using our intraductal microcatheters to deliver CAR-T or other immunotherapy.”

Atossa provided the following 2017 Financial Results:

Revenue and Cost of Revenue: For the years ended December 31, 2017 and 2016, they have no source of sustainable revenue and no associated cost of revenue.

Operating Expenses: Total operating expenses were $7,649,171 for the year ended December 31, 2017, which is a decrease of $319,419 or 4.0%, from the year ended December 31, 2016.  Operating expenses for 2017 consisted of general and administrative (G&A) expenses of $4,859,369, R&D expenses of $2,328,087, and impairment of their Acueity intangible assets of $461,715.

General and Administrative Expenses: G&A expenses were $4,859,369 for the year ended December 31, 2017, a decrease of $1,619,824, or 25.0% from the total G&A expenses for the year ended December 31, 2016, of $6,479,193.  G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses.  The 2017 decrease in G&A expense was primarily attributable to a reduction in payroll expenses resulting from decreased headcount, rent and exit costs incurred in 2016.  At the beginning of 2016, their strategy shifted away from the commercialization of medical devices towards focusing exclusively on the development of their pharmaceutical and microcatheter candidates.

Research and Development Expenses: R&D expenses for the year ended December 31, 2017, were $2,328,087, an increase of $1,557,660, or 202% from R&D expenses in 2016 of $770,427.  The increase in R&D expenses is attributed to salaries, manufacturing, and clinical trial expenses associated with their Endoxifen program for which manufacturing commenced at the beginning of 2017 and the clinical studies commenced in mid-2017.  They expect their R&D expenses to increase throughout 2018 as they commence Phase 2 clinical studies of Endoxifen, continue the clinical trial of fulvestrant administered via their microcatheters and as they continue the development of other indications and therapeutics, including CAR-T and immunotherapies administered via their intraductal microcatheters.

Cash and Cash Equivalents: As of December 31, 2017, the Company had approximately $7.2 million in cash and cash equivalents and working capital of approximately $6.7 million.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Announces 2017 Financial Results and Provides Company Update

SEATTLE, March 08, 2018– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announces …..

Read Full Article

Provider of Cloud Services, Fusion, Hosting Q4 & 2017 Results Conference Call Thursday, March 22

New your City-based Fusion (FSNN) is a leading provider of integrated cloud solutions to small, medium and large businesses, & is a single source for the cloud. Fusion’s advanced, proprietary cloud services platform enables the integration of leading-edge solutions in the cloud, including cloud communications, contact center, cloud connectivity, and cloud computing. Fusion’s innovative, yet proven cloud solutions lower their customers’ cost of ownership and deliver new levels of security, flexibility, scalability, and speed of deployment.

Fusion will hold a conference call on Thursday, March 22, 2018, at 10:30 a.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2017. Financial results will be issued in a press release prior to the call. Fusion CEO Matthew Rosen and CFO Michael Bauer will host the conference call, followed by a question and answer period.

To access the call, you dial Toll-free 1-888-882-4478 domestically, & the International dial-in number is 1-323-794-2149. The Conference ID is 1597159.

Michael Bauer, Fusion’s CFO, recently stated, “We are very excited to complete the Birch transaction. The combined company is projected to have approximately $575 million in pro forma annual revenue and over $150 million in pro forma annual Adjusted EBITDA, including over $20 million in expected cost synergies.” 
To learn more about Fusion (Nasdaq: FSNN) & Goldman Sachs (GS) and to track their progress please visit the Vista Partners Coverage Pages. 

Fusion Sets Fourth Quarter and Full Year 2017 Financial Results Conference Call for Thursday, March 22, 2018 at 10:30 a.m. ET

NEW YORK, March 08, 2018– Fusion, a leading provider of cloud services, will hold a conference call on Thursday, March 22, 2018 at 10:30 a.m. Eastern time to discuss its results for the fourth quarter …..

Read Full Article

HIIQ Heading To Roth Capital Growth Stock Conference in Dana Point, California March 13th

Health Insurance Innovations, Inc. (NasdaqGM: HIIQ) is a market leading cloud-based technology platform and distributor of innovative health insurance products that are affordable and meet the needs of health insurance plan shoppers. HIIQ helps develop insurance products through their relationships with best-in-class insurance companies and markets them via its broad distribution network of licensed insurance agents across the nation, its call center network and its unique online capability. HIIQ’s Consumer Division includes, a website for researching, comparing and purchasing short-term health insurance products online and, a free website that compares and ranks all health insurance plans and uses objective data to publish unbiased health insurance market analyses and other consumer advocacy research.

HIIQ announced this week that it will present at the 30th Annual Roth Capital Growth Stock Conference in Dana Point, California.  The presentation is scheduled for Tuesday, March 13, 2018, at 11:00 a.m. PDT.

Recently, HIIQ announced that it expects annual revenue for 2018 to be between $290 million and $300 million or grow approximately 15% to 20% year-over-year, adjusted EBITDA to be between $54 million and $57 million or grow approximately 20% to 25% year-over-year and adjusted EPS to be between $2.45 and $2.55 or grow approximately 48% to 55% year-over-year. These guidance numbers are based on the Company’s current method of accounting for revenue. As an emerging growth company, it will be adopting the revised revenue recognition standard, known as ASC 606, in the fourth quarter of 2018.

To learn more about HIIQ and to track its ongoing progress please visit the Vista Partners HIIQ Coverage Page.

Health Insurance Innovations, Inc. To Present at the 30th Annual Roth Capital Growth Stock Conference on March 13, 2018

TAMPA, Fla., March 07, 2018– Health Insurance Innovations, Inc., a leading cloud-based technology platform and distributor of affordable health plans, today announced that it will present at the 30th …..

Read Full Article